Verso Biosense signs agreement with Homerton University Hospital

We are delighted to announce the signing of a product collaboration agreement with Homerton University Hospital.

Under the agreement, Homerton will utilise our uterine monitoring platform, collaborating with Verso to help refine the technology and biosensing platform to meet the needs of its fertility patients.

Our platform captures critical in-vivo, biosensing data for optimisation and personalisation of IVF treatment, providing actionable insights for clinicians and patients.

Homerton University Hospital is one of the leading IVF and fertility centres in the UK and is recognised as an innovator in embracing methods and systems that provide better and safer patient care. This includes reviewing and collaborating on novel technologies for the treatment of IVF and fertility.

Joseph Cefai, Head of Product Development, commented:

“We are honoured to have partnered with Homerton University Hospital, a leader in pioneering fertility treatment, to introduce this transformational product to patients. Our monitoring platform has the potential to transform fertility treatment for millions of people and I am excited by what the future holds for the business and the impact it can have on the lives of so many.”